Complicated course of facial cellulitis caused by Staphylococcus aureus in a 13-year-old boy with neutropenia - an adverse event analysis

• Authors: Marta Rorat , Ernest Kuchar , Leszek Szenborn , Tomasz Jurek
• Languages of publication: EN

Abstracts

EN

Keywords

EN

Cellulitis; Neutropenia; Adverse event; Management; Staphylococci

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2013
• Volume: 8
• Issue: 2
• Pages: 220-224

Dates

published

1 - 4 - 2013

online

23 - 1 - 2013

Contributors

author

Marta Rorat

author

Ernest Kuchar

• Department of Paediatrics and Infectious Diseases, Wroclaw Medical University, Bujwida 44, 50-345, Wroclaw, Poland

author

Leszek Szenborn

• Department of Paediatrics and Infectious Diseases, Wroclaw Medical University, Bujwida 44, 50-345, Wroclaw, Poland

author

Tomasz Jurek

• Department of Forensic Medicine, Wroclaw Medical University, Mikulicza-Radeckiego 4, 50-345, Wroclaw, Poland

References

• [1] Krasagakis K., Valachis A., Maniatakis P., Krüger-Krasagakis S., Samonis G., Tosca A.D., Analysis of epidemiology, clinical features and management of erysipelas, Int. J. Dermatol., 2010, 49, 1012–1017 http://dx.doi.org/10.1111/j.1365-4632.2010.04464.x[WoS][Crossref]
• [2] Stevens D.L., Bisno A.L., Chambers H.F., Everett E.D., Dellinger P., Goldstein E.J., et al., Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections, Clin. Infect. Dis., 2005, 41, 1373–1406 http://dx.doi.org/10.1086/497143[Crossref]
• [3] Celestin R., Brown J., Kihiczak G., Schwartz R.A., Erysipelas: a common potentially dangerous infection, Acta Dermatovenerol. Alp. Panonica. Adriat., 2007, 16, 123
• [4] Bartholomeeusen S., Vandenbroucke J., Truyers C., Buntinx F., Epidemiology and comorbidity of erysipelas in primary care, Dermatology., 2007, 215, 118–122 http://dx.doi.org/10.1159/000104262[Crossref][WoS]
• [5] Jorup-Rönström C., Epidemiological, bacteriological and complicating features of erysipelas, Scand. J. Infect. Dis., 1986, 18, 519–524 http://dx.doi.org/10.3109/00365548609021656[Crossref]
• [6] Lazzarini L., Conti E., Tositti G., de Lalla F., Erysipelas and cellulitis: clinical and microbiological spectrum in an Italian tertiary care hospital, J. Infect. 2005, 51, 383–389 http://dx.doi.org/10.1016/j.jinf.2004.12.010[Crossref]
• [7] Krasagakis K., Samonis G., Maniatakis P., Georgala S., Tosca A., Bullous erysipelas: clinical presentation, staphylococcal involvement and methicillin resistance, Dermatology., 2006, 212, 31 http://dx.doi.org/10.1159/000089019[Crossref]
• [8] Müller-Lühr M., Breyer N., Martin A., Haacke H., Erysipelas in neutropenia of unknown origin, successfully treated with r-metHuG-CSF (filgrastim), Ann. Hematol., 1994, 69, 97–98 http://dx.doi.org/10.1007/BF01698490[Crossref]
• [9] Leclerc S., Teixeira A., Mahé E., Descamps V., Crickx B., Chosidow O., Recurrent erysipelas: 47cases, Dermatology., 2007, 214, 52–57 http://dx.doi.org/10.1159/000096913[WoS]
• [10] Bartholomeeusen S., Vandenbroucke J., Truyers C., Buntinx F., Epidemiology and comorbidity of erysipelas in primary care, Dermatology., 2007, 215, 118–122 http://dx.doi.org/10.1159/000104262[Crossref][WoS]
• [11] Krasagakis K., Samonis G., Valachis A., Maniatakis P., Evangelou G., Tosca A., Local complications of erysipelas: a study of associated risk factors, Clin. Exp. Dermatol., 2011, 36, 351–354 http://dx.doi.org/10.1111/j.1365-2230.2010.03978.x[Crossref]
• [12] Wolfson J.S., Sober A.J., Rubin R.H., Dermatologic manifestations of infections in immunocompromised patients, Medicine (Baltimore)., 1985, 64, 115–133
• [13] Glauser M., Empiric therapy of bacterial infections in patients with severe neutropenia., Diagn. Microbiol. Infect. Dis., 1998, 31, 467–472 http://dx.doi.org/10.1016/S0732-8893(98)00038-8[Crossref]
• [14] Hughes W.T., Armstrong D., Bodey G.P., Bow E.J., Brown A.E., Calandra T., et al., 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer, Clin. Infect. Dis., 2002, 34, 730–751 http://dx.doi.org/10.1086/339215[Crossref]
• [15] Institute of Medicine: To err is human: building a safer health system. National Academy Press, Washington, 2000
• [16] Schito G.C., Debbia E.A., Pesce A., Susceptibility of respiratory strains of Staphylococcus aureus to fifteen antibiotics: results of a collaborative surveillance study (1992–1993). The Alexander Project Collaborative Group, J. Antimicrob. Chemother., 1996, 38, 97–106 http://dx.doi.org/10.1093/jac/38.suppl_A.97[Crossref]
• [17] Talan D.A., Krishnadasan A., Gorwitz R.J., Fosheim G.E., Limbago B., Albrecht V., et al., EMERGEncy ID Net Study Group, Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008, Clin. Infect. Dis. 2011, 53, 144–149 http://dx.doi.org/10.1093/cid/cir308[Crossref]
• [18] Jones M.E., Karlowsky J.A., Draghi D.C., Thornsberry C., Sahm D.F., Nathwani D., Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy, Int. J. Antimicrob. Agents., 2003, 22, 406–419 http://dx.doi.org/10.1016/S0924-8579(03)00154-7[Crossref]
• [19] Sader H.S., Flamm R.K., Farrell D.J., Jones R.N., Activity Analyses of Staphylococcal Isolates From Pediatric, Adult, and Elderly Patients: AWARE Ceftaroline Surveillance Program, Clin. Infect. Dis., 2012, 55, 181–186 http://dx.doi.org/10.1093/cid/cis560[WoS][Crossref]
• [20] Deotale V., Mendiratta D.K., Raut U., Narang P., Inducible clindamycin resistance in Staphylococcus aureus isolated from clinical samples. Indian J. Med. Microbiol., 2010, 28, 124–126 http://dx.doi.org/10.4103/0255-0857.62488[WoS][Crossref]
• [21] Fridkin S.K., Hageman J.C., Morrison M., Sanza L.T., Como-Sabetti K., Jernigan J.A., et al., Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Methicillin-resistant Staphylococcus aureus disease in three communities, N. Engl. J. Med., 2005, 352, 1436–1444 http://dx.doi.org/10.1056/NEJMoa043252[Crossref]
• [22] Moran G.J., Krishnadasan A., Gorwitz R.J., Fosheim G.E., McDougal L.K., Carey R.B., et al., EMERGEncy ID Net Study Group, Methicillin resistant S. aureus infections among patients in the emergency department, N. Engl. J. Med., 2006, 355, 666–674 http://dx.doi.org/10.1056/NEJMoa055356[Crossref]
• [23] Morgan M., Treatment of MRSA soft tissue infections: an overview, Injury., 2011, 42 Suppl 5, 11–17 http://dx.doi.org/10.1016/S0020-1383(11)70127-9[Crossref]
• [24] Shimizu. T, Tokuda Y., Necrotizing fasciitis, Intern. Med., 2010, 49, 1051–1057 http://dx.doi.org/10.2169/internalmedicine.49.2964[WoS][Crossref]

Identifiers

DOI

10.2478/s11536-012-0106-9